HK1074393A1 - Desmopressin in an orodispersible dosage form - Google Patents

Desmopressin in an orodispersible dosage form

Info

Publication number
HK1074393A1
HK1074393A1 HK05106142A HK05106142A HK1074393A1 HK 1074393 A1 HK1074393 A1 HK 1074393A1 HK 05106142 A HK05106142 A HK 05106142A HK 05106142 A HK05106142 A HK 05106142A HK 1074393 A1 HK1074393 A1 HK 1074393A1
Authority
HK
Hong Kong
Prior art keywords
desmopressin
dosage form
orodispersible dosage
orodispersible
dosage
Prior art date
Application number
HK05106142A
Other languages
English (en)
Inventor
Anders Nilsson
Hans Lindner
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9936186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1074393(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2003/002368 external-priority patent/WO2003094886A2/fr
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of HK1074393A1 publication Critical patent/HK1074393A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK05106142A 2002-05-07 2005-07-20 Desmopressin in an orodispersible dosage form HK1074393A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0210397.6A GB0210397D0 (en) 2002-05-07 2002-05-07 Pharmaceutical formulations
PCT/IB2002/004036 WO2003094885A1 (fr) 2002-05-07 2002-09-20 Formulation pharmaceutique sublinguale a base de desmopressine
PCT/IB2003/002368 WO2003094886A2 (fr) 2002-05-07 2003-05-07 Preparations pharmaceutiques

Publications (1)

Publication Number Publication Date
HK1074393A1 true HK1074393A1 (en) 2005-11-11

Family

ID=9936186

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05106142A HK1074393A1 (en) 2002-05-07 2005-07-20 Desmopressin in an orodispersible dosage form

Country Status (22)

Country Link
US (14) US7560429B2 (fr)
EP (1) EP1501534B1 (fr)
KR (1) KR100632455B1 (fr)
CN (2) CN1981745A (fr)
AR (3) AR039092A1 (fr)
AT (1) ATE333886T1 (fr)
AU (2) AU2002337419A1 (fr)
DK (1) DK1501534T5 (fr)
ES (1) ES2266820T4 (fr)
GB (1) GB0210397D0 (fr)
HK (1) HK1074393A1 (fr)
IL (1) IL164519A (fr)
MX (1) MXPA04010926A (fr)
MY (1) MY131153A (fr)
PL (1) PL208482B1 (fr)
RU (1) RU2292903C2 (fr)
SI (1) SI1501534T1 (fr)
TW (1) TWI315202B (fr)
UA (1) UA85664C2 (fr)
UY (2) UY27683A1 (fr)
WO (2) WO2003094885A1 (fr)
ZA (1) ZA200408596B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
US20040236673A1 (en) * 2000-10-17 2004-11-25 Eder Jeff Scott Collaborative risk transfer system
US20080256069A1 (en) * 2002-09-09 2008-10-16 Jeffrey Scott Eder Complete Context(tm) Query System
US20080027769A1 (en) 2002-09-09 2008-01-31 Jeff Scott Eder Knowledge based performance management system
US20110040631A1 (en) * 2005-07-09 2011-02-17 Jeffrey Scott Eder Personalized commerce system
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
CA2545194C (fr) * 2003-11-10 2014-10-21 Seymour H. Fein Compositions pharmaceutiques comportant de la desmopressine faiblement dosee
DK1530967T3 (da) * 2003-11-13 2006-07-03 Ferring Bv Blisterpakning og dertil hörende fast dosisform
GB0406048D0 (en) * 2004-03-18 2004-04-21 Ardana Bioscience Ltd Drug formulations
US20090043637A1 (en) * 2004-06-01 2009-02-12 Eder Jeffrey Scott Extended value and risk management system
US7972621B2 (en) 2004-06-03 2011-07-05 R.P. Scherer Technologies, Llc Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
US8713025B2 (en) 2005-03-31 2014-04-29 Square Halt Solutions, Limited Liability Company Complete context search system
SE0600482L (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
US8498915B2 (en) 2006-04-02 2013-07-30 Asset Reliance, Inc. Data processing framework for financial services
US7788434B2 (en) * 2006-12-15 2010-08-31 Microchip Technology Incorporated Interrupt controller handling interrupts with and without coalescing
EP1967202A1 (fr) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Utilisation d'antagonistes LHTH pour le traitement des symptômes de tractus urinaires faibles, en particulier la vessie hyperactive et/ou hyperactivité du détrusor
ES2319054B1 (es) 2007-08-06 2010-02-12 Gp Pharm S.A. Composicion farmaceutica oral de desmopresina.
RU2472539C2 (ru) * 2007-08-06 2013-01-20 Аллерган, Инк. Способы и устройства для доставки препарата десмопрессина
CN101372504B (zh) * 2007-08-22 2011-05-18 深圳翰宇药业股份有限公司 一种纯化去氨加压素的方法
US20100121307A1 (en) * 2007-08-24 2010-05-13 Microfabrica Inc. Microneedles, Microneedle Arrays, Methods for Making, and Transdermal and/or Intradermal Applications
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
EP3225249B1 (fr) 2008-05-21 2018-11-07 Ferring B.V. Desmopressine orodispersible augmentant la période initiale de sommeil non perturbé par la nycturie
WO2010075327A1 (fr) * 2008-12-22 2010-07-01 Serenity Pharmaceuticals Corporation Composition de desmopressine
SG172344A1 (en) 2008-12-22 2011-07-28 Allergan Inc Intranasal desmopressin administration
AU2015261630B2 (en) * 2008-12-22 2017-09-14 Acerus Pharmaceuticals USA, LLC Intranasal desmopressin administration
CA2765221C (fr) * 2009-06-18 2017-10-03 Allergan, Inc. Administration sure de desmopressine
ES2712989T3 (es) * 2009-10-30 2019-05-17 Ix Biopharma Ltd Forma de dosificación sólida de disolución rápida
GB0920041D0 (en) * 2009-11-16 2009-12-30 Univ Aston Tablet
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
CN104606128B (zh) 2010-03-29 2018-02-23 辉凌公司 一种快速溶解药物组合物
CN103347494A (zh) * 2010-10-08 2013-10-09 R·P·舍勒科技有限责任公司 使用淀粉的口服疫苗快速溶解剂型
WO2013037708A1 (fr) 2011-09-16 2013-03-21 Ferring B.V. Composition pharmaceutique à dissolution rapide
JP6259454B2 (ja) 2012-07-12 2018-01-10 フェリング ベスローテン フェンノートシャップ ジクロフェナク製剤
US20150306170A1 (en) * 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release
TW201422254A (zh) 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
US20160045687A1 (en) * 2013-03-26 2016-02-18 Optinose As Nasal administration
MX2016001032A (es) * 2013-07-23 2017-10-31 Allergan Inc Metodos y composiciones que comprenden desmopresina en combinacion con un inhibidor de 5-alfa reductasa.
JP2016525548A (ja) * 2013-07-23 2016-08-25 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉ� Β−３アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物
WO2015063602A1 (fr) 2013-10-29 2015-05-07 Ferring B.V. Desmopressine et glycémie
KR20150144209A (ko) * 2014-06-16 2015-12-24 훼링 비.브이. 안정화된 데스모프레신 또는 이의 약학적으로 허용가능한 염을 함유 약학 조성물
KR20170097045A (ko) 2014-11-20 2017-08-25 알레간 인코포레이티드 알파-아드레날린성 수용체 길항제와 조합된 데스모프레신을 포함하는 방법 및 조성물
ITUB20156821A1 (it) * 2015-12-09 2017-06-09 Altergon Sa CAPSULE DI GELATINA MOLLE A RILASCIO pH INDIPENDENTE
WO2018130603A1 (fr) 2017-01-11 2018-07-19 Ferring B.V. Composition pharmaceutique à disintégration rapide
CN108113974A (zh) * 2018-02-05 2018-06-05 上海祺宇生物科技有限公司 一种多孔性空心胶囊的制备方法以及由此制备的胶囊
US10940088B1 (en) 2020-01-09 2021-03-09 King Saud University Method of preparing low dose pharmaceutical formulations
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2023023182A1 (fr) * 2021-08-19 2023-02-23 Mind Medicine, Inc. Formulations de comprimés lyophilisés orodispersibles de diéthylamide d'acide d-lysergique pour des applications thérapeutiques

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4285858A (en) 1979-10-30 1981-08-25 Mt. Sinai School Of Medicine Of The City University Of N.Y. Vasopressin analogs
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4263283A (en) * 1980-05-16 1981-04-21 Ferring Pharmaceuticals, Inc. Method for prophylaxis and/or treatment of sickle cell disease
US4371316A (en) * 1981-03-23 1983-02-01 Michael Ivic Control for a bilge pump
GB2111423B (en) 1981-12-02 1985-06-26 Wyeth John & Brother Ltd Making quick-dissolving pills
DE3275121D1 (en) 1981-12-11 1987-02-19 Wyeth John & Brother Ltd Process for preparing solid shaped articles
CA1208558A (fr) * 1982-10-07 1986-07-29 Kazuo Kigasawa Medicament oral
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
SE8306367L (sv) 1983-11-18 1985-05-19 Ferring Ab Antidiuretiskt verkande farmaceutiskt preparat
US4863737A (en) 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
US4623283A (en) * 1984-06-13 1986-11-18 Mobil Oil Corporation Method for controlling water influx into underground cavities
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4731360A (en) 1985-08-16 1988-03-15 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
IE60941B1 (en) 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4878892A (en) 1987-02-10 1989-11-07 Drug Delivery Systems Inc. Electrolytic transdermal delivery of polypeptides
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US4878592A (en) * 1988-06-28 1989-11-07 Zarn, Inc. Apparatus for segregated refuse collection
US5350741A (en) * 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
EP0381345B1 (fr) * 1989-01-30 1994-07-13 Corint, Ltd. Composition aqueuse à base de desmopressine-CMC
US5091186A (en) 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
TW279133B (fr) 1990-12-13 1996-06-21 Elan Med Tech
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
SE9101022D0 (sv) 1991-01-09 1991-04-08 Paal Svedman Medicinsk suganordning
US6746678B1 (en) 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
AU653026B2 (en) * 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5464387A (en) 1991-07-24 1995-11-07 Alza Corporation Transdermal delivery device
US5466464A (en) 1991-12-24 1995-11-14 Yamanouchi Pharmaceutical Co., Ltd. Intrabuccally disintegrating preparation and production thereof
US5298256A (en) * 1992-04-28 1994-03-29 Corint, Ltd. Desmopressin buccal patch composition
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
US5343672A (en) 1992-12-01 1994-09-06 Scherer Ltd R P Method for manufacturing freeze dried dosages in a multilaminate blister pack
CA2090738C (fr) * 1993-02-24 1996-05-21 Hema-Quebec Utilisation du paf
SE9300937L (sv) 1993-03-19 1994-09-20 Anne Fjellestad Paulsen Komposition för oral administrering av peptider
SE501677C2 (sv) 1993-06-18 1995-04-10 Ferring Bv Biologiskt aktiva vasopressinanaloger, farmaceutiska preparat innehållande dem samt deras användning för framställning av läkemedel
US5985835A (en) * 1993-12-23 1999-11-16 Ferring B.V. Desmopressin for nocturia, incontinence and enuresis
US5482931A (en) 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
US5500413A (en) 1993-06-29 1996-03-19 Ferring Ab Process for manufacture of 1-deamino-8-D-arginine vasopressin
DK0710243T3 (da) 1993-06-29 2000-10-16 Ferring Bv Syntese af cykliske peptider
ES2158898T3 (es) 1993-06-29 2001-09-16 Ferring Bv Composiciones para la administracion de desmopresina por via nasal.
US5674850A (en) 1993-12-23 1997-10-07 Ferring Ab High purity desmopressin produced in large single batches
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
AU692506B2 (en) * 1993-11-17 1998-06-11 Ibah, Inc. Transparent liquid for encapsulated drug delivery
WO1995018602A1 (fr) * 1994-01-11 1995-07-13 Alkermes Controlled Therapeutics, Inc. FORME PHARMACEUTIQUE DE DESMOPRECYNE (dDAVP) POUR ADMINISTRATION PAR VOIE ORALE
US5595761A (en) * 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
SE9400918L (sv) 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
KR0134152B1 (ko) 1994-05-23 1998-04-14 이형도 의약품 투여용 피부흠집 형성장치
US5611806A (en) 1994-05-23 1997-03-18 Samsung Electro-Mechanics Co., Ltd. Skin perforating device for transdermal medication
GB9410388D0 (en) 1994-05-24 1994-07-13 Erba Carlo Spa Method for the preparation of 9-amino camptothecin
US5495898A (en) * 1994-07-13 1996-03-05 Champion Road Machinery Limited Blade control system for motor graders
SE518619C2 (sv) 1994-12-09 2002-10-29 Gs Dev Ab Komposition för reglerad frisättning innehållande monokaproin
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
IL113459A (en) 1995-04-23 2000-07-16 Electromagnetic Bracing System Electrophoretic cuff apparatus
AU5740496A (en) 1995-05-22 1996-12-11 General Hospital Corporation, The Micromechanical device and method for enhancing delivery of compounds through the skin
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
US5849322A (en) 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
DE19602757A1 (de) 1996-01-26 1997-07-31 Boehringer Mannheim Gmbh Feste Instant-Release-Darreichungsformen und Verfahren zu ihrer Herstellung
US5843016A (en) 1996-03-18 1998-12-01 Physion S.R.L. Electromotive drug administration for treatment of acute urinary outflow obstruction
TW411277B (en) 1996-05-13 2000-11-11 Hisamitsu Pharmaceutical Co Percutaneous tape preparation containing fentanyl
ZA975326B (en) 1996-06-18 1998-01-14 Alza Corp Device and method for enhancing transdermal flux of agents being delivered or sampled.
US5763398A (en) 1996-06-20 1998-06-09 Ferring B.V. Nasal administration of desmopressin
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
SE9604341D0 (sv) 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
FR2758195B1 (fr) 1997-01-09 1999-02-26 Sgs Thomson Microelectronics Coprocesseur d'arithmetique modulaire comprenant deux circuits de multiplication operant en parallele
US5985385A (en) 1997-05-23 1999-11-16 No Fire Technologies, Inc. Fire and heat protection wrap for conduits, cable trays, other electrical transmission lines and gas and oil pipelines
US5932745A (en) 1997-07-30 1999-08-03 American Home Products Corporation Process for converting propargylic amine-N-oxides to enaminones
US6194407B1 (en) 1997-07-30 2001-02-27 American Home Products Corporation Tricyclic pyrido vasopressin agonists
US6511974B1 (en) 1997-07-30 2003-01-28 Wyeth Tricyclic vasopressin agonists
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6248358B1 (en) * 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US7153845B2 (en) 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US20040018241A1 (en) 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US5843477A (en) * 1997-09-30 1998-12-01 Bayer Corporation Lubricants for use in tabletting
US6248636B1 (en) * 1998-05-28 2001-06-19 Samsung Electronics Co., Ltd. Method for forming contact holes of semiconductor memory device
US6322532B1 (en) 1998-06-24 2001-11-27 3M Innovative Properties Company Sonophoresis method and apparatus
US7138393B2 (en) 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
US6090803A (en) 1998-07-24 2000-07-18 American Home Products Corporation Tricyclic vasopressin agonists
US6423346B1 (en) * 1998-08-25 2002-07-23 Basf Health & Nutrition A/S Fish gelatinous composition for use as an ingredient in tablets
US6148232A (en) 1998-11-09 2000-11-14 Elecsys Ltd. Transdermal drug delivery and analyte extraction
GB9827292D0 (en) 1998-12-12 1999-02-03 Univ Strathclyde Freeze drying
US6406455B1 (en) 1998-12-18 2002-06-18 Biovalve Technologies, Inc. Injection devices
US20060025387A1 (en) * 1998-12-23 2006-02-02 Cytoscan Sciences Llc Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
GB9901819D0 (en) 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
US6297234B1 (en) 1999-02-04 2001-10-02 American Home Products Corporation Arylthiophene vasopressin agonists
US6620807B1 (en) 1999-02-04 2003-09-16 Wyeth Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists
US6235900B1 (en) 1999-02-04 2001-05-22 American Home Products Corporation Tricyclic pyridine N-oxides vasopressin agonists
US6344451B1 (en) 1999-02-04 2002-02-05 American Home Products Pyrrolobenzodiazepine carboxyamide vasopressin agonists
TWI271198B (en) * 1999-02-15 2007-01-21 Dainippon Sumitomo Pharma Co Tables disintegrating rapidly in the oral cavity
ATE342097T1 (de) 1999-02-18 2006-11-15 Biovalve Technologies Inc Elektroaktive pore
AR014640A1 (es) * 1999-02-23 2001-03-28 Univ Nac Quilmes UNA COMPOSICíoN FARMACÉUTICA INHIBIDORA DE LA DISEMINACIoN METASTÁSICA DURANTE LA CIRUGíA DE UN TUMOR CANCEROSO, UN PROCEDIMENTO DE PREPARACIoN Y UN KIT PARA UNA FORMULACIoN INYECTABLE.
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6210699B1 (en) 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
GB2355454A (en) 1999-10-20 2001-04-25 Ferring Bv Antidiuretic agents
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US6558695B2 (en) 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
GB0000079D0 (en) 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
DE60144229D1 (de) 2000-01-07 2011-04-28 Valeritas Inc Injektionsvorrichtung
US20070032410A1 (en) * 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
GB0015601D0 (en) 2000-06-26 2000-08-16 Ferring Bv Novel antidiuretic agents
US6348486B1 (en) 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US7537795B2 (en) * 2000-10-26 2009-05-26 Alza Corporation Transdermal drug delivery devices having coated microprotrusions
EP1339442A4 (fr) 2000-11-30 2006-12-27 Biovalve Technologies Inc Systemes d'injection
EP2554196B1 (fr) 2000-11-30 2018-10-17 Valeritas, Inc. Systèmes de mesure et de distribution de fluide
EP1345646A2 (fr) 2000-12-14 2003-09-24 Georgia Tech Research Corporation Appareils a microaiguilles et fabrication
US7027478B2 (en) 2000-12-21 2006-04-11 Biovalve Technologies, Inc. Microneedle array systems
DE20221841U1 (de) 2001-03-16 2008-05-21 Alza Corp., Mountain View Transdermal-Pflaster zum Verabreichen von Fentanyl
US7022699B2 (en) 2001-04-12 2006-04-04 Wyeth Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
DE60222879T2 (de) * 2001-04-12 2008-07-24 Wyeth Cyclohexylphenyl vasopressin agonisten
DK1381370T3 (da) 2001-04-12 2007-05-21 Wyeth Corp N-Biphenylcarbonyl- og N-phenylpyridylcarbonyl-substituerede bi- og tricykliske azepiner og diazepiner som vasopressin-agonister
US6872405B2 (en) * 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
US6509040B1 (en) * 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
US6667277B2 (en) 2001-08-24 2003-12-23 National Starch And Chemical Investment Holding Corporation Water dispersible starch based physical form modification of agricultural agents
US7615234B2 (en) 2001-09-11 2009-11-10 Glide Pharmaceutical Technologies Limited Drug delivery technology
JP4157036B2 (ja) 2001-09-13 2008-09-24 キッセイ薬品工業株式会社 ヒドロキシノルエフェドリン誘導体塩酸塩の結晶
US20050127107A1 (en) * 2001-09-21 2005-06-16 Pierre Mbonyumuhire Dosing device with a medium reservoir and a pump device
US6723077B2 (en) 2001-09-28 2004-04-20 Hewlett-Packard Development Company, L.P. Cutaneous administration system
US6893655B2 (en) 2001-10-09 2005-05-17 3M Innovative Properties Co. Transdermal delivery devices
US7169772B2 (en) 2001-11-16 2007-01-30 Astellas Pharma Inc. 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivatives or salts thereof
AU2003233118B8 (en) 2002-05-07 2009-07-30 Ferring Bv Desmopressin in an orodispersible dosage form
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
WO2003097080A1 (fr) 2002-05-15 2003-11-27 Sun Pharmaceutical Industries Limited Composition aqueuse stable de peptide
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
ITMI20021684A1 (it) * 2002-07-29 2004-01-29 Therapicon Srl Composizione farmaceutica di peptide nasale
GB2421689B (en) 2002-08-05 2007-03-07 Caretek Medical Ltd Drug delivery system
CA2516547A1 (fr) 2002-09-30 2004-04-15 Alza Corporation Methode et dispositif d'administration de medicaments presentant des microprojections revetues comprenant des vasoconstricteurs
WO2004033457A1 (fr) * 2002-10-09 2004-04-22 Toray Industries, Inc. Remedes ou produits preventifs pour la frequence urinaire ou l'incontinence urinaire, et derives de morphinane presentant un groupe heterocylique contenant de l'azote
US7383084B2 (en) 2002-10-31 2008-06-03 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
DE60333311D1 (de) 2002-11-14 2010-08-19 Ube Industries Kosmetische zusammensetzung
DE10259934B3 (de) 2002-12-20 2004-10-14 H.C. Starck Gmbh Verfahren zur Herstellung von Formteilen aus Niob oder Tantal durch elektrochemisches Ätzen und so erhältliche Formteile
AR042815A1 (es) 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
US20040155167A1 (en) * 2003-02-07 2004-08-12 Ergodontics System and method of mounting a display screen via a pendulum type mount
CA2521492C (fr) * 2003-04-28 2010-09-21 Astellas Pharma Inc. Derive de 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine ou sel de celui-ci
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US7094545B2 (en) 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
ES2236640T3 (es) 2003-04-30 2005-07-16 Ferring B.V. Forma posologica de la desmopresina.
EP1638468B1 (fr) 2003-06-30 2007-08-15 Alza Corporation Methode d'enduction de microprojections de per age de la peau
CN1826099B (zh) * 2003-07-25 2010-06-09 凡林有限公司 固体剂型药物组合物及其制造方法
PT1500390E (pt) 2003-07-25 2005-10-31 Ferring Bv Composicao farmaceutica como forma de dosagem solida e metodo de producao
US6930932B2 (en) 2003-08-27 2005-08-16 Hewlett-Packard Development Company, L.P. Data signal reception latch control using clock aligned relative to strobe signal
US20050106226A1 (en) 2003-10-24 2005-05-19 Cormier Michel J. Pretreatment method and system for enhancing transdermal drug delivery
CA2543084A1 (fr) 2003-10-24 2005-05-12 Alza Corporation Dispositif et procede d'amelioration de l'administration transdermique de medicament
ES2377647T3 (es) * 2003-10-31 2012-03-29 Alza Corporation Aplicador auto-actuado para ordenamiento de microproyecciones
CA2545194C (fr) 2003-11-10 2014-10-21 Seymour H. Fein Compositions pharmaceutiques comportant de la desmopressine faiblement dosee
DK1530967T3 (da) 2003-11-13 2006-07-03 Ferring Bv Blisterpakning og dertil hörende fast dosisform
US7344725B2 (en) 2003-11-25 2008-03-18 Alcon, Inc. Use of inorganic nanoparticles to stabilize hydrogen peroxide solutions
US7018653B2 (en) 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
CA2490601C (fr) 2003-12-29 2006-05-02 Ferring B.V. Methode de preparation d'une forme pharmaceutique solide de desmopressine
DK1550439T3 (da) 2003-12-29 2006-04-03 Ferring Bv Fremgangsmåde til fremstilling af faste dosisformer af desmopressin
KR20060134050A (ko) 2004-01-09 2006-12-27 알자 코포레이션 주파수 보조 경피성 약제 전달 방법 및 시스템
SI1797109T1 (sl) * 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe
US7097776B2 (en) 2004-10-22 2006-08-29 Hewlett-Packard Development Company, L.P. Method of fabricating microneedles
US20060093658A1 (en) * 2004-10-26 2006-05-04 Gayatri Sathyan Apparatus and method for transdermal delivery of desmopressin
US20080009800A1 (en) 2004-12-02 2008-01-10 Nickel Janice H Transdermal drug delivery device
US7180274B2 (en) 2004-12-10 2007-02-20 Aimtron Technology Corp. Switching voltage regulator operating without a discontinuous mode
EP1845946A2 (fr) 2005-02-10 2007-10-24 Orexo AB Nouvelles compositions pharmaceutiques utiles pour l'administration transmuqueuse de medicaments
BRPI0610036A2 (pt) 2005-04-22 2010-05-18 Wyeth Corp derivados de benzofuranil alcanamina e usos destes como agonìstico de 5-ht2c
GT200600165A (es) 2005-04-22 2007-03-14 Derivados dihidrobenzofuranos y usos de los mismos
MX2007012883A (es) * 2005-04-22 2007-12-10 Wyeth Corp Derivados de dihidrobenzofurano y usos de los mismos.
AR054035A1 (es) * 2005-04-22 2007-05-30 Wyeth Corp Derivados benzodioxano y benzodioxolano y uso de los mismos
US7856263B2 (en) 2005-04-22 2010-12-21 Travanti Pharma Inc. Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis
PE20061297A1 (es) 2005-04-22 2006-12-24 Wyeth Corp Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
JP2008538784A (ja) 2005-04-24 2008-11-06 ワイス 膀胱機能を調節するための方法
SE0600482L (sv) 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
RU2472539C2 (ru) 2007-08-06 2013-01-20 Аллерган, Инк. Способы и устройства для доставки препарата десмопрессина
WO2010075327A1 (fr) 2008-12-22 2010-07-01 Serenity Pharmaceuticals Corporation Composition de desmopressine

Also Published As

Publication number Publication date
US9919025B2 (en) 2018-03-20
KR100632455B1 (ko) 2006-10-11
AR107948A2 (es) 2018-07-04
CN1981745A (zh) 2007-06-20
DK1501534T3 (da) 2006-11-20
MXPA04010926A (es) 2005-02-14
ES2266820T3 (es) 2007-03-01
US20180280469A1 (en) 2018-10-04
TWI315202B (en) 2009-10-01
UY27796A1 (es) 2003-11-28
WO2004041153A2 (fr) 2004-05-21
RU2004130435A (ru) 2005-08-10
US20120071538A1 (en) 2012-03-22
US20150150938A1 (en) 2015-06-04
US8143225B2 (en) 2012-03-27
US20070265207A1 (en) 2007-11-15
UY27683A1 (es) 2003-12-31
WO2003094885A1 (fr) 2003-11-20
EP1501534B1 (fr) 2006-07-26
IL164519A (en) 2009-09-22
US20100056436A1 (en) 2010-03-04
SI1501534T1 (sl) 2006-12-31
IL164519A0 (en) 2005-12-18
WO2004041153A3 (fr) 2004-08-26
CN1649615A (zh) 2005-08-03
US20120322734A1 (en) 2012-12-20
ATE333886T1 (de) 2006-08-15
US20050232997A1 (en) 2005-10-20
AU2003299480A8 (en) 2004-06-07
AR039092A1 (es) 2005-02-09
US7579321B2 (en) 2009-08-25
US20090318665A1 (en) 2009-12-24
US9504647B2 (en) 2016-11-29
US20090005432A1 (en) 2009-01-01
US20080274951A1 (en) 2008-11-06
PL375497A1 (en) 2005-11-28
AR039794A1 (es) 2005-03-02
US20170112895A1 (en) 2017-04-27
TW200400054A (en) 2004-01-01
ZA200408596B (en) 2006-06-28
MY131153A (en) 2007-07-31
US20040138098A1 (en) 2004-07-15
AU2002337419A1 (en) 2003-11-11
CN1319592C (zh) 2007-06-06
AU2003299480A1 (en) 2004-06-07
UA85664C2 (ru) 2009-02-25
EP1501534A2 (fr) 2005-02-02
US20210161810A1 (en) 2021-06-03
DK1501534T5 (da) 2014-12-15
US7947654B2 (en) 2011-05-24
US8802624B2 (en) 2014-08-12
US7405203B2 (en) 2008-07-29
US7560429B2 (en) 2009-07-14
US10307459B2 (en) 2019-06-04
GB0210397D0 (en) 2002-06-12
PL208482B1 (pl) 2011-05-31
US20160175246A1 (en) 2016-06-23
US9220747B2 (en) 2015-12-29
KR20050009999A (ko) 2005-01-26
RU2292903C2 (ru) 2007-02-10
US7799761B2 (en) 2010-09-21
ES2266820T4 (es) 2014-12-30

Similar Documents

Publication Publication Date Title
HK1074393A1 (en) Desmopressin in an orodispersible dosage form
HK1087008A1 (en) An allergen dosage form
HK1119989A1 (en) Game device
AU2003300017A8 (en) Microprocessor and microprocessor operation
GB0206461D0 (en) Improvements in vaccination
IL172195A0 (en) Thiotungstate analogues and uses thereof
IL162604A0 (en) Conformationally constrained c-backbone cyclic peptides
AU2003228236A8 (en) Dynamic time metered delivery
EP1501722A4 (fr) Ameliorations apportees aux beaupres
GB2394878B (en) Hooklink and lead discharge system
HK1209050A1 (en) Survivin-derived peptides and use thereof
AU2003302173A8 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
GB2396181B (en) Posts
AU2003239679A8 (en) Improvements in greetins cards
GB0311936D0 (en) Improvements in devices
HRP20041102A2 (en) Progestagenic dosage units
GB0524480D0 (en) Posts
EP1699809A4 (fr) Peptide provenant du liquide amniotique et ses utilisations
EP1551330A4 (fr) Ameliorations dans la technologie de l'apport
GB0212744D0 (en) Improvements in devices
GB0206910D0 (en) Improvements in devices
GB0203803D0 (en) Improvements in syringes
GB0225549D0 (en) Improvements in medical devices
GB0222255D0 (en) Peptides and their use
GB0227910D0 (en) Proein structure and uses thereof

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230506